JP2019525771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525771A5 JP2019525771A5 JP2019520935A JP2019520935A JP2019525771A5 JP 2019525771 A5 JP2019525771 A5 JP 2019525771A5 JP 2019520935 A JP2019520935 A JP 2019520935A JP 2019520935 A JP2019520935 A JP 2019520935A JP 2019525771 A5 JP2019525771 A5 JP 2019525771A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- protein
- polypeptide
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 48
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 210000004698 lymphocyte Anatomy 0.000 claims 40
- 231100000433 cytotoxic Toxicity 0.000 claims 39
- 230000001472 cytotoxic effect Effects 0.000 claims 39
- 102000004169 proteins and genes Human genes 0.000 claims 33
- 108090000623 proteins and genes Proteins 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 10
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- -1 LIGHT Proteins 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359612P | 2016-07-07 | 2016-07-07 | |
| US62/359,612 | 2016-07-07 | ||
| PCT/US2017/041241 WO2018009894A1 (en) | 2016-07-07 | 2017-07-07 | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525771A JP2019525771A (ja) | 2019-09-12 |
| JP2019525771A5 true JP2019525771A5 (enExample) | 2020-08-13 |
| JP7093771B2 JP7093771B2 (ja) | 2022-06-30 |
Family
ID=59366537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520935A Active JP7093771B2 (ja) | 2016-07-07 | 2017-07-07 | プログラム死１リガンド１（ｐｄ－ｌ１）結合タンパク質及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11141434B2 (enExample) |
| EP (1) | EP3481867B1 (enExample) |
| JP (1) | JP7093771B2 (enExample) |
| KR (1) | KR102630017B1 (enExample) |
| CN (1) | CN109843921B (enExample) |
| AU (1) | AU2017292889B2 (enExample) |
| BR (1) | BR112019000185A2 (enExample) |
| CA (1) | CA3030156A1 (enExample) |
| DK (1) | DK3481867T3 (enExample) |
| EA (1) | EA201990230A1 (enExample) |
| ES (1) | ES3000676T3 (enExample) |
| IL (1) | IL264104B2 (enExample) |
| MA (1) | MA45595A (enExample) |
| MX (1) | MX2019000149A (enExample) |
| NZ (1) | NZ750005A (enExample) |
| SG (1) | SG11201900138TA (enExample) |
| WO (1) | WO2018009894A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| CN111167008A (zh) | 2013-12-05 | 2020-05-19 | 免疫系统公司 | 利用射频电学膜击穿（rf-emb）的癌症免疫疗法 |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| JP6723249B2 (ja) | 2015-01-30 | 2020-07-15 | アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー | 軟部組織を切除するためのシステムおよび方法 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| CA3011460A1 (en) | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| KR20190127655A (ko) | 2016-10-19 | 2019-11-13 | 프로디자인 소닉스, 인크. | 음향학에 의한 친화성 세포 추출 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| AU2019236204B2 (en) | 2018-03-15 | 2026-02-26 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| EP4143300A1 (en) | 2020-04-28 | 2023-03-08 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4572786A1 (en) | 2022-08-17 | 2025-06-25 | Purdue Research Foundation | Universal natural killer cells derived from human pluripotent stem cells and method of use |
| JP2026504180A (ja) | 2023-01-30 | 2026-02-03 | カイマブ・リミテッド | 抗体 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| AU2000202A (en) | 2000-10-31 | 2002-05-15 | Pr Pharmaceuticals Inc | Methods and compositions for enhanced delivery of bioactive molecules |
| EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| EP2336293B1 (en) | 2003-10-08 | 2016-02-10 | Wilson Wolf Manufacturing Corporation | Cell culture methods and devices utilizing gas permeable materials |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CN101104640A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| EP2424887B1 (en) | 2009-04-30 | 2015-09-30 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inducible interleukin-12 |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8809050B2 (en) | 2009-12-08 | 2014-08-19 | Wilson Wolf Manufacturing | Methods of cell culture for adoptive cell therapy |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| HRP20210642T1 (hr) | 2010-11-12 | 2021-05-28 | Nektar Therapeutics | Konjugati il-2 ostatka i polimera |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2598055T3 (es) | 2011-10-21 | 2017-01-25 | Cell Medica Limited | Dispositivo para la expansión aséptica de células |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| AU2013262485B2 (en) | 2012-05-18 | 2017-12-14 | Wilson Wolf Manufacturing, LLC | Improved methods of cell culture for adoptive cell therapy |
| IL288241B2 (en) | 2012-06-11 | 2023-10-01 | Wilson Wolf Mfg Corporation | Improved cell culture methods for stress cell therapy |
| WO2014133568A1 (en) | 2013-03-01 | 2014-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
| AU2013379772B2 (en) | 2013-03-01 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor-reactive T cells from tumor |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| JP6560667B2 (ja) | 2013-06-24 | 2019-08-14 | ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ | 気体透過性細胞培養作業のための閉鎖系装置および方法 |
| US10233425B2 (en) | 2013-09-16 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | CD137 enrichment for efficient tumor infiltrating lymphocyte selection |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| KR20230085225A (ko) | 2014-03-20 | 2023-06-13 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 입양 세포 요법을 위한 종양-침윤 림프구 |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| EP3838288A1 (en) | 2014-06-11 | 2021-06-23 | polybiocept GmbH | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
| HRP20201656T1 (hr) * | 2014-09-16 | 2021-03-05 | Innate Pharma | Neutralizacija inhibitornih putova u limfocitima |
| JP6686008B2 (ja) | 2014-10-02 | 2020-04-22 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| IL320860A (en) | 2014-12-19 | 2025-07-01 | Dana Farber Cancer Inst Inc | Chimeric antigen receptors and methods of using them |
| SMT202400133T1 (it) | 2016-10-26 | 2024-05-14 | Iovance Biotherapeutics Inc | Restimolazione di linfociti infiltranti il tumore crioconservati |
| JP7780248B2 (ja) | 2017-01-06 | 2025-12-04 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用 |
| JP7349365B2 (ja) | 2017-05-10 | 2023-09-22 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用 |
| AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
-
2017
- 2017-07-07 CN CN201780054791.8A patent/CN109843921B/zh active Active
- 2017-07-07 CA CA3030156A patent/CA3030156A1/en active Pending
- 2017-07-07 NZ NZ750005A patent/NZ750005A/en unknown
- 2017-07-07 AU AU2017292889A patent/AU2017292889B2/en active Active
- 2017-07-07 BR BR112019000185-9A patent/BR112019000185A2/pt active Search and Examination
- 2017-07-07 US US16/316,019 patent/US11141434B2/en active Active
- 2017-07-07 IL IL264104A patent/IL264104B2/en unknown
- 2017-07-07 SG SG11201900138TA patent/SG11201900138TA/en unknown
- 2017-07-07 ES ES17740873T patent/ES3000676T3/es active Active
- 2017-07-07 JP JP2019520935A patent/JP7093771B2/ja active Active
- 2017-07-07 MA MA045595A patent/MA45595A/fr unknown
- 2017-07-07 MX MX2019000149A patent/MX2019000149A/es unknown
- 2017-07-07 DK DK17740873.9T patent/DK3481867T3/da active
- 2017-07-07 KR KR1020197003606A patent/KR102630017B1/ko active Active
- 2017-07-07 EP EP17740873.9A patent/EP3481867B1/en active Active
- 2017-07-07 EA EA201990230A patent/EA201990230A1/ru unknown
- 2017-07-07 WO PCT/US2017/041241 patent/WO2018009894A1/en not_active Ceased
-
2021
- 2021-09-10 US US17/472,552 patent/US12023355B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525771A5 (enExample) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| CN114072427B (zh) | 抗dll3嵌合抗原受体及其用途 | |
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| TW201904997A (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| CN113891718A (zh) | 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞 | |
| WO2015172341A1 (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| US20250000976A1 (en) | Anti-bcma single domain antibodies and therapeutic constructs | |
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| US20230265185A1 (en) | Anti-cd22 single domain antibodies and therapeutic constructs | |
| AU2024276506A1 (en) | Immune effector cell and use thereof | |
| HK40110214A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40110781A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40098926A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40065826B (zh) | 抗dll3嵌合抗原受体及其用途 |